| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD012984 |
| P932 | PMC publication ID | 6494409 |
| P2093 | author name string | Daniel G Ezra | |
| Mario Salvi | |||
| Swan Kang | |||
| Shirin Hamed Azzam | |||
| P2860 | cites work | Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 |
| Smoking was associated with poor response to intravenous steroids therapy in Graves' ophthalmopathy. | Q50965755 | ||
| Psychosocial morbidity of Graves' orbitopathy. | Q51925700 | ||
| Graves' disease. | Q54276950 | ||
| Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ. | Q54405781 | ||
| The Incidence of Graves' Ophthalmopathy in Olmsted County, Minnesota | Q57482586 | ||
| Modification of the Classification of the Eye Changes of Graves' Disease | Q67021590 | ||
| Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture | Q71477264 | ||
| Pathogenesis of Graves' ophthalmopathy--current understanding | Q73397377 | ||
| Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy | Q73555606 | ||
| CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity | Q83847859 | ||
| Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists | Q84434183 | ||
| Treatment of active corticosteroid-resistant graves' orbitopathy | Q87246219 | ||
| Orbital radiotherapy for adult thyroid eye disease | Q24201984 | ||
| Rituximab for thyroid-associated ophthalmopathy | Q24202845 | ||
| Surgical orbital decompression for thyroid eye disease | Q24234593 | ||
| Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management | Q26782424 | ||
| Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search | Q26800562 | ||
| The evaluation and treatment of graves ophthalmopathy | Q26862144 | ||
| Graves' ophthalmopathy | Q28274196 | ||
| Evolving concepts of rheumatoid arthritis | Q29618020 | ||
| Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial | Q30481543 | ||
| Multiple imputation by chained equations for systematically and sporadically missing multilevel data | Q31131831 | ||
| Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach | Q33647383 | ||
| Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation | Q34434772 | ||
| Orbital radiotherapy for Graves' ophthalmopathy | Q34599785 | ||
| Therapeutic strategies for rheumatoid arthritis | Q35140855 | ||
| Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. | Q35606170 | ||
| Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy | Q36515498 | ||
| Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers | Q36568033 | ||
| Cigarette smoking and thyroid eye disease: a systematic review | Q36596473 | ||
| The IL-6/sIL-6R complex as a novel target for therapeutic approaches | Q36804420 | ||
| The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 | ||
| Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy | Q37110191 | ||
| Immune mechanisms in thyroid eye disease. | Q37254482 | ||
| Current insights into the pathogenesis of Graves' orbitopathy | Q37520866 | ||
| Medical management of thyroid eye disease | Q38130235 | ||
| Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy | Q38325670 | ||
| Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis | Q38843328 | ||
| Graves' ophthalmopathy: current concepts regarding pathogenesis and management | Q39489563 | ||
| Orbital decompression for the management of thyroid eye disease: An analysis of outcomes and complications | Q41042475 | ||
| T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. | Q43455387 | ||
| Classification of the eye changes of Graves' disease. | Q43650306 | ||
| Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy | Q43804248 | ||
| The Psychosocial and Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and Predictors of Change in Quality of Life | Q47952058 | ||
| P433 | issue | 3 | |
| P921 | main subject | tocilizumab | Q425154 |
| eye disease | Q3041498 | ||
| P577 | publication date | 2018-03-25 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Tocilizumab for thyroid eye disease | |
| P478 | volume | 2018 |
Search more.